On the evening of June 8, Shanghai Stock Exchange accepted the application of Chemclin Diagnostics Corporation for listing Sci-Tech innovation board (STAR Market). For this time, Chemclin Diagnostics collaborates with heavyweight industrial capital, relying on its strong strength in infectious disease detection.

On October 26, Chemclin Diagnostics Corporation delivered the good news that it will be listed on the Sci-Tech innovation board in the IPO meeting.

Established in 2007, Beijing Chemclin Biotechnology Co., Ltd. is one of the earliest Chinese companies specializing in the development of clinical immunological diagnostic products. Chemclin Diagnostics focuses in the development, production, marketing and service of clinical in vitro diagnostic （IVD） products. At present, the company has established a photoluminescence technology platform with independent intellectual property rights, and LiCA series instruments and reagents based on this technology platform.

Compared with the traditional immunodiagnostic technology, chemiluminescence has the advantages of high automation degree, good specificity, high accuracy and wide detection range, and has become one of the most competitive enterprises in this field in China. It is worth mentioning that LiCA series products, as the strategic focus of Comme Diagnostics, have been growing rapidly in recent years, with an annual compound growth rate of over 45% and accounting for more than 65% of its revenue in 2019.

According to the report, the IPO of Chemclin is to raise funds for the new in vitro diagnostic reagent production base, the research and development of in vitro diagnostic reagents and supporting products, LiCA reagent and supporting instrument research and development (laboratory) and other projects. These will be conducive to the company to expand capacity, meet the growing market demand and the company's business development needs.

On August 21-23 this year, the booth of Chemclin Diagnostics at the 17th China Association Clinical Laboratory Practice Expo (CACLP) was crowded with attendees.